Boc-Lys(2-bromo-Z)-OH

Boc-Lys(2-bromo-Z)-OH is a protected lysine derivative designed for peptide and peptidomimetic synthesis, featuring an N-terminal Boc protecting group and a side-chain functional handle that bears a 2-bromo substituent. The lysine scaffold provides a protected primary amine for controlled coupling chemistry, while the bromo-bearing side chain enables downstream derivatization through selective C-Br reactivity after peptide assembly. This reagent is commonly used by peptide chemistry groups and custom peptide manufacturers to introduce a lysine-based branching point for later functionalization, including attachment of side-chain-modified motifs and construction of chemically defined analogs.

1. Side-Chain Functionalization

Boc-Lys(2-bromo-Z)-OH is used as a lysine building block when a peptide needs a latent electrophilic handle for post-assembly modification. Researchers in peptide chemistry and chemical biology incorporate this residue during peptide synthesis to generate a defined bromo-functional side chain that can be carried forward into subsequent derivatization steps, enabling preparation of libraries of side-chain-modified peptides and peptidomimetics. The presence of the Boc-protected backbone functionality supports routine peptide coupling workflows, while the 2-bromo substituent provides a chemically addressable site for downstream functional group installation under conditions compatible with the rest of the peptide framework.

2. Modified Peptide Synthesis

Boc-Lys(2-bromo-Z)-OH supports the synthesis of modified peptide segments where lysine's side chain must remain controlled during assembly and later converted into a functionalized analog. Custom peptide manufacturing teams use this type of protected lysine derivative to prepare peptides bearing chemically distinct lysine side-chain chemistry, such as analogs used for structure-activity relationship studies or for mapping how side-chain substitution patterns influence peptide behavior in biochemical assays. The protected lysine amino functionality helps maintain fidelity during stepwise chain elongation, while the incorporated 2-bromo-Z side-chain motif allows the final peptide to be diversified after the core sequence is completed.

3. Pharmaceutical Intermediate Development

Boc-Lys(2-bromo-Z)-OH is also applied as a protected amino acid intermediate for building higher-complexity molecules that require a lysine-derived electrophilic site. Medicinal chemistry and process development groups use this reagent to access defined, functionalized intermediates that can be carried into subsequent coupling, substitution, or elaboration steps to generate advanced scaffolds. The combination of a Boc-protected amino acid framework with a bromo-bearing side-chain handle supports a practical development strategy in which the peptide/peptidomimetic-like portion is assembled under controlled conditions and the side-chain reactivity is reserved for later synthetic stages.

4. Chemical Biology Probe Building

Boc-Lys(2-bromo-Z)-OH is selected by chemical biology teams when they need a lysine-based position for controlled attachment of probe moieties after peptide synthesis. By incorporating this residue into a peptide backbone, investigators can prepare probes with a predetermined modification site, improving reproducibility across probe batches used in mechanistic studies and binding-format experiments. The 2-bromo functionality provides a handle for installing probe-related substituents while the Boc-protected amino acid architecture supports reliable peptide assembly, helping ensure that labeling chemistry occurs at the intended lysine side-chain location rather than through less controlled side reactions.

1. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

2. Myotropic activity of allatostatins in tenebrionid beetles

3. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy